Tagged with EU

AIFD - Association of Research-Based Pharmaceutical Companies Pharmaceutical Executive and Focus Reports are of course about the industry but also about the people making it happen. So before anything would you like to introduce yourself to our readers and expose the career path that has led you to take the helm of Turkey’s leader in the pharmaceutical…

AIFD - Association of Research-Based Pharmaceutical Companies In an environment where the line between generic and innovator companies is less and less relevant, due to the growing trend of innovators integrating generics products in their portfolio through acquisitions, to what extent has the role of association evolved? Despite the growing trend of integrating innovative products with generics,…

Ferring Pharmaceuticals Turkey The company entered the Turkish market in 2005, and made important product launches in 2008. You have been General Manager of Ferring Turkey over those last 7 years. Can you come back on the positive and negative experiences for you during this time? I believe that Ferring’s start in 2005…

Association of Pharmaceutical Research and Development (APRaD) What was the vision behind the creation of APRaD back in 2007 and what was lacking in the market at that time that called for such an association? APRaD originated from a group of general managers of international pharmaceutical companies who felt that the interests of international pharma were not…

Abex Pharmaceutica Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations. Could you compare the two and tell us what position you enjoyed the most? I think I prefer the creative…

Eisai Europe As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary Hendler (GH): Eisai are currently present in 17 European markets as Eisai and several others via distributors. However it is…

Watson Pharmaceuticals UK Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since its creation in 1984, Watson was a generic pharmaceutical company that was predominantly US based until the acquisition of Arrow…

Orient Europharma Co. You founded Orient Europharma in 1982, nearly 30 years ago. As you approach the 30 year mark, how has the company evolved to the way it is today, and how would you describe the company to our readers? I left Upjohn in 1982 and established Orient Europharma (OEP) as a…

Zodiac Pharmaceuticals What would you recommend in terms of increasing the competitiveness and growth of the Brazilian pharmaceutical industry? The Brazilian pharmaceutical industry needs to improve its R&D capabilities. I personally think that the country can’t build a strong pharmaceutical industry based only on generics. Generics are an important part of the…

Association of Innovative Pharmaceutical Manufacturers (AIPM) Hungary - Innovatív Gyógyszergyártók Egyesülete With various new government measures, the pharmaceutical and healthcare sector in Hungary has been undergoing quite a turbulent period recently. But if we first take a step back… Can you explain to our readers what has attracted most of your members to have a presence in the Hungarian market? V.N.I.:…

Otsuka (Philippines) Pharmaceutical You were appointed President and General Manager of Otsuka Philippines in 2008. Can you please start by giving to our readers an overview of Otsuka activities in the country as well as the company’s biggest achievements since you have been heading the company? Otsuka Philippines was incorporated in December 1997…

Chiesi Pharmaceuticals BV The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was shifting towards a cost-containment structure. What drove Chiesi’s decision to start-up in the Netherlands? Our respiratory product, Foster, was one…